Tavapadon
Small moleculeexperimental
Clinical trial activity
21 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
7
Phase 3
4
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT01981694)
Timeline
Indications
Mechanism of action
- Dopamine receptorPARTIAL AGONIST
Dopamine receptor partial agonist
- Dopamine D1 receptorPARTIAL AGONIST
Dopamine D1 receptor partial agonist
- Dopamine D5 receptorPARTIAL AGONIST
Dopamine D5 receptor partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Oc2ncccc2C(F)(F)F)ccc1-c1c(C)c(=O)[nH]c(=O)n1C- Mol. weight
- 391.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3697617 ↗
Also known as
- pf06649751
- pf-06649751
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06895356 | Phase 1 | Mar 26, 2025 | AbbVie |
| NCT05610189 | Phase 1 | Dec 15, 2022 | Cerevel Therapeutics, LLC |
| NCT05581823 | Phase 1 | Oct 19, 2022 | Cerevel Therapeutics, LLC |
| NCT05404542 | Phase 1 | May 10, 2022 | Cerevel Therapeutics, LLC |
| NCT05404529 | Phase 1 | Apr 29, 2022 | Cerevel Therapeutics, LLC |
| NCT04760769 | Phase 3 | Feb 24, 2021 | Cerevel Therapeutics, LLC |
| NCT04542499 | Phase 3 | Oct 27, 2020 | Cerevel Therapeutics, LLC |
| NCT04241393 | Phase 1 | Feb 4, 2020 | Cerevel Therapeutics, LLC |
| NCT04295642 | Phase 1 | Jan 8, 2020 | Cerevel Therapeutics, LLC |
| NCT04223193 | Phase 3 | Jan 6, 2020 | Cerevel Therapeutics, LLC |
| NCT04201093 | Phase 3 | Dec 13, 2019 | Cerevel Therapeutics, LLC |
| NCT03185481 | Phase 2 | Jun 30, 2017 | Pfizer |
| NCT03121664 | Phase 1 | Apr 7, 2017 | Pfizer |
| NCT02847650 | Phase 2 | Oct 17, 2016 | Pfizer |
| NCT02687542 | Phase 2 | Mar 3, 2016 | Pfizer |
| NCT02373072 | Phase 1 | Mar 1, 2015 | Pfizer |
| NCT02262767 | Phase 1 | Nov 1, 2014 | Pfizer |
| NCT02224664 | Phase 1 | Oct 1, 2014 | Pfizer |
| NCT02066909 | Phase 1 | Feb 1, 2014 | Pfizer |
| NCT01981694 | Phase 1 | Nov 1, 2013 | Pfizer |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cerevel Therapeutics, LLC | For profit | 10 | 10 | 2 | 2019 |
| Pfizer | For profit | 9 | 9 | 2 | 2013 |
| AbbVie | For profit | 2 | 2 | 2 | 2025 |
3 organizations
Page 1 / 1